ArticleCureus2026
Fatal Rapidly Progressive Interstitial Lung Disease in Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Dermatomyositis in a Brazilian Patient: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-melanoma differentiation-associated gene 5 (anti-MDA5) dermatomyositis (DM) is a subtype of idiopathic inflammatory myopathy. It is characterized by prominent cutaneous manifestations, minimal muscle involvement, and a strong association with interstitial lung disease (ILD), particularly rapidly progressive ILD (RP-ILD), a life-threatening complication with high early mortality. Although RP-ILD is less frequently reported in Western populations than in Asian cohorts, severe presentations may still occur. We report the case of a previously healthy 35-year-old woman who presented with typical DM features and progressive dyspnea. Chest computed tomography (CT) revealed an organizing pneumonia pattern consistent with ILD. Despite early aggressive immunosuppression, the patient developed pneumomediastinum, pneumothorax, and worsening diffuse ground-glass opacities. Anti-MDA5 positivity was confirmed, and even after rescue therapy and intensive supportive care, the patient died. This case illustrates the fulminant course of anti-MDA5 DM with RP-ILD and severe structural complications, emphasizing the need for early recognition and aggressive immunosuppression even in populations with a lower reported prevalence of RP-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.